Mutations in the body’s cells randomly accumulate as part of the aging process, and most are harmless. For some people, genetic changes in blood cells can develop in genes that play roles in initiating leukemia and lymphoma even though such people don’t have the blood cancers, the scientists report Oct…
“According to research evidence, survival rates are considered equal,” explained dean Nancy Fahrenwald of the South Dakota State University College of Nursing. Working through the South Dakota Women’s Cancer Network, the South Dakota Comprehensive Cancer Control Program and seven cancer treatment centers in the state, Fahrenwald got responses from 1,093 breast cancer survivors who had been diagnosed in the last five years. To determine which of the nine independent variables tipped the scales toward mastectomy, she turned to associate professor Chris Saunders of the mathematics and statistics department. “The statistics were not meant to be innovative but to provide an answer that is robust and rigorous,” said Saunders, who used logistic regression to analyze the survey results…
A new computational model developed in the laboratory of Salvatore Torquato, a Professor of Chemistry at Princeton University, may help illuminate the conditions surrounding tumor dormancy and the switch to a malignant state. Published today in PLOS ONE, the so-called cellular automaton model simulated various scenarios of tumor growth leading to tumor suppression, dormancy or proliferation. “The power of the model is that it lets people to test medically realistic scenarios,” Torquato said. In future collaborations, these scenarios could be engineered in laboratory experiments and the observed outcomes could be used to calibrate the model. …
This switch is driven by p53, the well-documented tumor-suppressing protein. The UNC researchers showed that increasing the level of p53 in scar-forming cells significantly reduced scarring and improved heart function after heart attack. The finding, which was published today in the journal Nature, shows that it is possible to limit the damage wrought by heart attacks, which strike nearly one million people in the United States each year. Heart disease accounts for one in four deaths every year…
“To develop next generation nanomedicines with superior anti-cancer attributes, we must understand the correlation between their physicochemical properties — specifically, particle size — and their interactions with biological systems,” explains Jianjun Cheng, an associate professor of materials science and engineering at the University of Illinois at Urbana-Champaign. In a recent study, published in the Proceedings of the National Academy of Sciences, Cheng and his collaborators systematically evaluated the size-dependent biological profiles of three monodisperse drug-silica nanoconjugates at 20, 50 and 200 nm…
Glioblastoma is the most common and deadliest form of brain cancer. The majority of these tumors – known as primary glioblastomas – occur in the elderly without evidence of a less malignant precursor. …
“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. …
“Cdk4/6 inhibitors used in cancer treatment don’t differentiate between the two molecules. The effectiveness of blocking both proteins at once has not been demonstrated to date,” explains Malumbres…
“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. Allott, Stephen Freedland, MD, associate professor of surgery at Duke University School of Medicine, and colleagues, analyzed data from 843 men who underwent radical prostatectomy after a prostate cancer diagnosis and who never took statins before surgery. …
“Cdk4/6 inhibitors used in cancer treatment don’t differentiate between the two molecules. The effectiveness of blocking both proteins at once has not been demonstrated to date,” explains Malumbres. …